Bio-Thera Reports P-I Study Results of BAT8006 for the Treatment of Advanced Solid Tumors
Shots:
- The P-I study & the clinical results of a P-I dose escalation study evaluating BAT8006 (folate-receptor-α-ADC) at Bethune Obstetrics and Gynecology Forum in China
- The results from the 29 patients enrolled in the study showed ORR (31.0%) & DCR (86.2%). From 12 patients with ovarian cancer with TPS >25%, ORR (58.3%) & DCR (91.7%), ~75% of ovarian cancer patients have FRα expression >25% based on FRα expression epidemiological studies
- 2 patients with non-ovarian tumors, incl. breast cancer & endometrial carcinoma experienced partial responses with manageable safety profiles with TRAEs & no patients were withdrawn from the study due to TRAEs. BAT8006 is being studied in a P-Ib study in China with 4 dose expansion cohorts
Ref: Prnewswire | Image: Bio-Thera
Related News:- Bio-Thera Solutions Demonstrated High Similarity Between BAT1706, a proposed biosimilar of bevacizumab and Reference Bevacizumab
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
